The Beneficial and Adverse Effects of Raloxifene in Menopausal Women: A Mini Review
10.6118/jmm.2018.24.3.183
- Author:
Imaneh KHORSAND
1
;
Reyhaneh KASHEF
;
Masumeh GHAZANFARPOUR
;
Elaheh MANSOURI
;
Sareh DASHTI
;
Talat KHADIVZADEH
Author Information
1. Department of Parasitology and Mycology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
- Publication Type:Meta-Analysis
- Keywords:
Depression;
Lipoproteins;
Raloxifene hydrochloride;
Sleep wake disorders;
Venous thromboembolism
- MeSH:
Breast Neoplasms;
Cognition;
Depression;
Female;
Humans;
Lipoproteins;
Memory;
Mild Cognitive Impairment;
Odds Ratio;
Pelvic Organ Prolapse;
Plasma;
Prolapse;
Pulmonary Embolism;
Raloxifene Hydrochloride;
Risk Reduction Behavior;
Sleep Wake Disorders;
Venous Thromboembolism;
Venous Thrombosis
- From:Journal of Menopausal Medicine
2018;24(3):183-187
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVES: The present mini review aimed to summarize the existing knowledge regarding the beneficial and adverse effects of raloxifene in menopausal women. METHODS: This study is a review of relevant publications about the effects of raloxifene on sleep disorder, depression, venous thromboembolism, the plasma concentration of lipoprotein, breast cancer, and cognitive function among menopausal women. RESULTS: Raloxifene showed no significant effect on depression and sleep disorder. Verbal memory improved with administration of 60 mg/day of raloxifene while a mild cognitive impairment risk reduction by 33% was observed with administration of 120 mg/day of raloxifene. Raloxifene was associated with a 50% decrease in the need for prolapse surgery. The result of a meta-analysis showed a significant decline in the plasma concentration of lipoprotein in the raloxifene group compared to placebo (standardized mean difference, −0.43; 10 trials). A network meta-analysis showed that raloxifene significantly decreased the risk of breast cancer (relative risk, 0.572; 95% confidence interval, 0.327–0.881; P = 0.01). In terms of adverse effects of raloxifene, the odds ratio (OR) was observed to be 1.54 (P = 0.006), indicating 54% increase in the risk of deep vein thrombosis (DVT) while the OR for pulmonary embolism (PE) was 1.05, suggesting a 91% increase in the risk of PE alone (P = 0.03). CONCLUSIONS: Raloxifene had no significant effect on depression and sleep disorder but decreased the concentration of lipoprotein. Raloxifene administration was associated with an increased risk of DVT and PE and a decreased risk of breast cancer and pelvic organ prolapse in postmenopausal women.
